Mode of action - Briumvi UK
Reading Time: 2 minutes

Mode of action

This promotional website is intended for UK healthcare professionals only.

Briumvi® (ublituximab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.1 

BRIUMVI®
:
Mode of action
BRIUMVI®: the First glyco-engineered anti-CD20 antibody in MS1-4
Anti-CD20 without glyco-engineering
  • Certain sugar molecules can interfere with the
    binding of the Fc region of the anti-CD20 antibody
    to the Fc receptor.2,3
BRIUMVI® a glyco-engineered anti-CD20
  • Interfering sugar molecules were removed through
    glyco-engineering. 
  • Removal of these sugar molecules enhances the binding affinity of the Fc region of the anti-CD20 antibody to the Fc receptor.5,6

BRIUMVI® showed a median B-cell depletion of 97% after the first infusion in both Ultimate I and Ultimate II clinical studies.4

Figure adapted from Steinman L, et al., 2022

Day 1 - first infusion

150 mg BRIUMVI® by intravenous infusion1

Day 15 - secound infusion

450 mg BRIUMVI® by intravenous infusion1

Subsequent infusions

(every 24 weeks, starting from infusion 1)

450 mg BRIUMVI® by intravenous infusion1

In clinical trials, treatment with BRIUMVI® led to:

BRIUMVI® mode of action video
Play Video

BRIUMVI® (ublituximab) 150 mg concentrate for solution for infusion

BRIUMVI® (ublituximab) is indicated for the treatment of adult patients with relapsing forms of MS (RMS) with active disease defined by clinical or imaging features.1

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Neuraxpharm by email: info-uk@neuraxpharm.com.

NXUK/0225/02 Date of preparation: October 2025

References
1BRIUMVI® Summary of Product Characteristics.
2Ferrara C, Grau S, Jäger C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core 1 fucose Proc Natl Acad Sci U S A. 2011;108(31): 12669-12674. doi: 10.1073/pnas.1108455108.
3Sun Y, Izadi S, Callahan M, et al. Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity. J Biol Chem. 2021; 297(1): 100826. doi:10.1016/j.jbc.2021.100826.
4Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022; 387(8): 704-714. doi:10.1056/NEJMoa2201904.
5Fox E, Lovett-Racke AE, Gormley M, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420-429. doi:10.1177/1352458520918375.
6de Romeuf C, Dutertre C-A, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcRIIIA/CD16. Br J Haematol. 2008; 140(6): 635-643. doi:10.1111/.1365-2141.2007.06974.x. 
 
Abbreviations 
mITT, modified intention-to-treat; MS, multiple sclerosis; NK, natural killer.